BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.
BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9 genome editing patent. Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field. Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.